Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19301647 | IMMEDIATE RELEASE MULTILAYER TABLET | August 2025 | December 2025 | Allow | 4 | 1 | 0 | No | No |
| 19263736 | METHOD OF TREATING CANCER USING CaV2O6/CaSiO3/g-C3N4 NANOCOMPOSITE | July 2025 | September 2025 | Allow | 3 | 0 | 0 | No | No |
| 19238194 | PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE | June 2025 | March 2026 | Allow | 9 | 2 | 0 | Yes | No |
| 19174583 | TAMPER RESISTANT DOSAGE FORMS | April 2025 | July 2025 | Allow | 3 | 1 | 0 | No | No |
| 19047536 | NOVEL FORMULATION FOR LACOSAMIDE | February 2025 | August 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18953603 | TAMPER RESISTANT DOSAGE FORMS | November 2024 | February 2025 | Allow | 3 | 1 | 0 | No | No |
| 18921291 | PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE | October 2024 | March 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18830440 | COMPOSITION AND METHOD FOR REDUCING RISK OF HYPOCALCEMIA IN PERIPARTURIENT RUMINANT ANIMALS | September 2024 | March 2025 | Allow | 6 | 2 | 0 | Yes | No |
| 18801899 | CENTANAFADINE MULTIPHASIC CONTROLLED-RELEASE PHARMACEUTICAL FORMULATION | August 2024 | November 2025 | Allow | 15 | 4 | 0 | Yes | No |
| 18794390 | ADAGRASIB SOLID PHARMACEUTICAL COMPOSITIONS | August 2024 | February 2025 | Allow | 6 | 2 | 0 | Yes | No |
| 18760150 | FAST DISINTEGRATING TABLET | July 2024 | October 2025 | Allow | 15 | 2 | 0 | No | No |
| 18666141 | SHELF-STABLE FORMULATIONS OF BENZOYL PEROXIDE AND METHODS OF PRODUCING SAME | May 2024 | March 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18661506 | TCM THROAT TEA METHOD AND COMPOSITION | May 2024 | September 2025 | Abandon | 17 | 2 | 0 | Yes | No |
| 18629431 | ALLERGENIC PROTEIN FORMULATIONS FOR IMMUNOTHERAPY | April 2024 | February 2026 | Allow | 22 | 2 | 0 | Yes | No |
| 18618702 | COMPOSITION AND METHOD FOR REDUCING RISK OF HYPOCALCEMIA IN PERIPARTURIENT RUMINANT ANIMALS | March 2024 | August 2024 | Allow | 4 | 2 | 0 | Yes | No |
| 18609809 | OSMOTIC DOSAGE FORMS COMPRISING DEUTETRABENAZINE AND METHODS OF USE THEREOF | March 2024 | December 2025 | Allow | 21 | 2 | 0 | Yes | No |
| 18690069 | METAL-GLYCEROL DECORATED ANTIMICROBIAL POLYMER COMPOSITE | March 2024 | September 2025 | Abandon | 19 | 3 | 0 | Yes | Yes |
| 18585349 | Long Acting Injectable Formulation Comprising Risperidone And Biodegradable Polymers | February 2024 | April 2025 | Allow | 13 | 2 | 0 | Yes | No |
| 18434155 | COATED TABLETS FOR PH-DEPENDENT RELEASE OF BENZGALANTAMINE | February 2024 | September 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18419135 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | January 2024 | November 2025 | Allow | 22 | 1 | 0 | No | No |
| 18411236 | NOVEL IBUPROFEN AND ACETAMINOPHEN COMPOSITION | January 2024 | June 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18576386 | MICROBIAL TREATMENT SOLUTION AND METHOD OF PRODUCING MICROBIAL TREATMENT SOLUTION | January 2024 | August 2024 | Allow | 8 | 1 | 0 | No | No |
| 18518823 | METHOD OF MAKING GOLD NANOPARTICLES CAPPED WITH CARALLUMA SINAICA EXTRACT AND TREATMENT METHOD USING THE SAME | November 2023 | July 2024 | Allow | 8 | 2 | 0 | Yes | No |
| 18510816 | Multifunctional Nanoparticles For Prevention And Treatment Of Atherosclerosis | November 2023 | April 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18510590 | IMMEDIATE RELEASE MULTILAYER TABLET | November 2023 | December 2025 | Abandon | 25 | 3 | 0 | Yes | No |
| 18510585 | IMMEDIATE RELEASE MULTILAYER TABLET | November 2023 | January 2025 | Allow | 14 | 1 | 0 | No | No |
| 18560039 | TRIMODAL, PRECISION-TIMED PULSATILE RELEASE TABLET | November 2023 | March 2026 | Allow | 28 | 1 | 0 | Yes | No |
| 18387599 | COMPOSITIONS AND METHODS FOR TREATING PRURITIS ANI AND ANAL FISSURES | November 2023 | June 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18495149 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | October 2023 | September 2024 | Allow | 11 | 2 | 0 | No | No |
| 18491946 | NEW DRY POWDER COMPOSITION FOR PERORAL ADMINISTRATION | October 2023 | December 2025 | Allow | 26 | 1 | 0 | No | No |
| 18489379 | METHODS AND COMPOSITIONS FOR DELIVERING MYCOPHENOLIC ACID ACTIVE AGENTS TO NON-HUMAN MAMMALS | October 2023 | March 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18480820 | PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN | October 2023 | March 2026 | Abandon | 30 | 1 | 0 | No | No |
| 18478797 | LACOSAMIDE PHARMACEUTICAL COMPOSITION AND DOSAGE FORM THEREOF | September 2023 | March 2024 | Allow | 6 | 2 | 0 | Yes | No |
| 18371932 | PREPARATION CONTAINING SAXAGLIPTIN AND METHOD FOR PRODUCING THE SAME | September 2023 | August 2025 | Allow | 22 | 3 | 0 | No | No |
| 18464911 | Nicotine Tablet | September 2023 | October 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18244424 | 5-HYDROXYTRYPTOPHAN GASTRORETENTIVE DOSAGE FORMS | September 2023 | January 2026 | Abandon | 28 | 2 | 0 | No | Yes |
| 18463498 | AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF | September 2023 | January 2025 | Allow | 16 | 3 | 0 | No | No |
| 18229914 | COMPOSITIONS AND METHODS FOR TREATING PRURITIS ANI AND ANAL FISSURES | August 2023 | November 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18363002 | ANTIMICROBIAL COMPOSITION COMPRISING AN ALKYLDIMETHYLBENZYLAMMONIUM COMPOUND | August 2023 | August 2025 | Allow | 25 | 0 | 0 | Yes | No |
| 18217994 | METHODS FOR TREATMENT AND/OR PREVENTION OF VIRAL INFECTIONS | July 2023 | February 2026 | Abandon | 31 | 1 | 0 | No | No |
| 18213143 | ORAL BILAYER TABLETS COMPRISING ACETYLSALICYLIC ACID AND PSEUDOEPHEDRINE, METHODS OF PREPARING AND USING THEREOF | June 2023 | February 2025 | Allow | 20 | 2 | 0 | No | No |
| 18327229 | IMMEDIATE RELEASE MULTILAYER TABLET | June 2023 | December 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18314348 | AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF | May 2023 | September 2023 | Allow | 4 | 1 | 0 | No | No |
| 18136974 | Method for Controlling Hematophagous or Sap-Feeding Arthropods | April 2023 | January 2025 | Allow | 21 | 1 | 0 | No | No |
| 18304246 | COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION | April 2023 | September 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 18119192 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE | March 2023 | September 2025 | Abandon | 31 | 2 | 0 | No | No |
| 18024452 | Liquid Embolic Compositions with Controlled Release of Radiopaque and Therapeutic Compounds and Methods of Using the Same | March 2023 | December 2025 | Allow | 34 | 1 | 0 | Yes | No |
| 18175212 | Acetaminophen Formulation With Protection Against Toxic Effects of Overdose | February 2023 | April 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18169402 | PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE | February 2023 | August 2024 | Allow | 18 | 3 | 0 | Yes | No |
| 18021053 | METHOD FOR TREATING DERMATITIS | February 2023 | January 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18102471 | METHOD OF ENHANCING 5-HYDROXYTRYPTOPHAN (5-HTP) EXPOSURE | January 2023 | May 2025 | Allow | 27 | 2 | 0 | Yes | No |
| 18160953 | DELIVERY SYSTEMS FOR CONTROL OF BLEEDING IN TRANSURETHRAL PROSTATECTOMY | January 2023 | August 2025 | Allow | 31 | 2 | 0 | Yes | No |
| 18102014 | COMPOSITIONS AND METHODS FOR TREATING PRURITIS ANI AND ANAL FISSURES | January 2023 | September 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18006141 | FORMULATIONS OF 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOF | January 2023 | March 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18155240 | PHARMACEUTICAL COMPOSITION, COMPRISING POLMACOXIB AND PREGABALIN, FOR TREATMENT OF PAIN | January 2023 | September 2023 | Allow | 7 | 2 | 0 | Yes | No |
| 18005179 | ORAL SUSTAINED-RELEASE COMPOSITION FOR INSOLUBLE DRUG, AND PREPARATION METHOD THEREOF | January 2023 | October 2025 | Allow | 33 | 1 | 0 | No | No |
| 18013801 | METHOD FOR PREPARING COMPOUND AS PI3K INHIBITOR AND INTERMEDIATE COMPOUND FOR PREPARING SAME | December 2022 | December 2025 | Allow | 36 | 1 | 0 | No | No |
| 18009173 | INGESTIBLE DEVICE HAVING A SPIKE ASSEMBLY | December 2022 | May 2025 | Abandon | 29 | 0 | 0 | No | No |
| 18000166 | PRALSETINIB PHARMACEUTICAL COMPOSITIONS | November 2022 | March 2026 | Allow | 39 | 1 | 1 | Yes | No |
| 18070341 | COMBINATION SOLID ORAL DOSAGE FORMS OF GONADOTROPIN-RELEASING HORMONE ANTAGONISTS | November 2022 | October 2025 | Allow | 34 | 0 | 1 | No | No |
| 17922914 | NOVEL EXTENDED RELEASE COMPOSITION OF 2-(2- AMINOTHIAZOL-4-YL)-N-[4-(2{[(2R)-2-HYDROXY-2-PHENYLETHYL] AMINO} ETHYL) PHENYL] ACETAMIDE | November 2022 | December 2025 | Allow | 38 | 2 | 0 | Yes | No |
| 17922623 | NEW COMPOSITIONS FOR ORAL OR NASAL USE | November 2022 | December 2025 | Allow | 38 | 2 | 1 | Yes | No |
| 17963013 | METHOD AND DEVICE FOR IN VIVO TISSUE REGENERATION ON THE INTERIOR SURFACE OF HOLLOW ORGANS | October 2022 | June 2025 | Allow | 32 | 2 | 0 | Yes | No |
| 17938703 | RE-TREATMENT FOR OPHTHALMIC CORRECTION OF REFRACTION | October 2022 | July 2025 | Allow | 33 | 1 | 1 | Yes | No |
| 17916618 | METHODS OF FORMING PARTICLES BY CONTINUOUS DROPLET FORMATION AND DEHYDRATION | October 2022 | March 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 17957715 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF IMMUNE DEFICIENCY AND INFLAMMATION | September 2022 | September 2025 | Allow | 36 | 2 | 0 | Yes | No |
| 17916195 | COMPOSITION HAVING IMPROVED VOLUNTARY ACCEPTANCE | September 2022 | October 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17936361 | Novel Dietary Supplements | September 2022 | June 2024 | Allow | 21 | 2 | 0 | No | No |
| 17912638 | USE OF SLOW-RELEASING HYDROGEN SULFIDE ORGANIC DONOR ADT-OH IN THE PREPARATION OF DRUGS FOR TREATING NERVOUS SYSTEM DISEASES | September 2022 | October 2025 | Allow | 37 | 1 | 0 | No | No |
| 17945890 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | September 2022 | January 2024 | Allow | 16 | 1 | 0 | No | No |
| 17944494 | EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DISEASE | September 2022 | August 2025 | Abandon | 35 | 3 | 0 | No | No |
| 17902689 | STACKED TISSUE ENCAPSULATION DEVICE SYSTEMS WITH OR WITHOUT OXYGEN DELIVERY | September 2022 | February 2024 | Allow | 18 | 0 | 0 | Yes | No |
| 17887246 | ORAL FOOD CHALLENGE MEAL FORMULATIONS | August 2022 | September 2024 | Allow | 25 | 3 | 0 | Yes | No |
| 17877699 | 5-HYDROXYTRYPTOPHAN GASTRORETENTIVE DOSAGE FORMS | July 2022 | April 2023 | Allow | 9 | 2 | 0 | Yes | No |
| 17869978 | WOUND DRESSING AND A METHOD FOR PRODUCING THE SAME | July 2022 | December 2023 | Allow | 17 | 1 | 0 | Yes | No |
| 17855242 | IMMEDIATE RELEASE MULTILAYER TABLET | June 2022 | March 2023 | Allow | 9 | 1 | 0 | No | No |
| 17784453 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | June 2022 | April 2023 | Allow | 11 | 1 | 0 | No | No |
| 17837501 | ORAL ADMINISTRATION OF KETAMINE | June 2022 | January 2026 | Allow | 43 | 4 | 0 | No | No |
| 17757043 | DOSAGE FORM FOR USE IN TREATING OR PREVENTING OF A DISEASE | June 2022 | May 2023 | Allow | 11 | 2 | 0 | Yes | No |
| 17835435 | OSMOTIC DOSAGE FORMS COMPRISING DEUTETRABENAZINE AND METHODS OF USE THEREOF | June 2022 | January 2026 | Allow | 43 | 2 | 1 | No | No |
| 17833638 | SILICATE CONTAINING COMPOSITIONS AND METHODS OF TREATMENT | June 2022 | July 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17832229 | MICROPARTICLES CONTAINING LEUPROLIDE AND METHOD FOR PRODUCING THE SAME | June 2022 | March 2024 | Allow | 21 | 2 | 0 | No | Yes |
| 17829908 | PHARMACEUTICAL COMPOSITIONS | June 2022 | July 2023 | Allow | 14 | 2 | 0 | Yes | No |
| 17664513 | LACOSAMIDE PHARMACEUTICAL COMPOSITION AND DOSAGE FORM THEREOF | May 2022 | September 2023 | Allow | 16 | 1 | 0 | No | No |
| 17602393 | METHOD FOR CONTINUOUSLY PRODUCING AN ACTIVE INGREDIENT GRANULATE | May 2022 | October 2025 | Allow | 48 | 1 | 0 | No | No |
| 17775245 | POLYMERIC NANOPARTICLES THAT TARGET LIVER SINUSOIDAL ENDOTHELIAL CELLS TO INDUCE ANTIGEN-SPECIFIC IMMUNE TOLERANCE | May 2022 | October 2025 | Allow | 41 | 0 | 1 | No | No |
| 17735741 | AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF | May 2022 | June 2023 | Abandon | 13 | 2 | 0 | Yes | No |
| 17735784 | AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF | May 2022 | June 2023 | Abandon | 13 | 2 | 0 | Yes | No |
| 17773058 | USE OF NEUROSPORENE TO PROTECT THE SKIN FROM THE HARMFUL EFFECTS OF BLUE LIGHT | April 2022 | September 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17772336 | FRAGRANCE OR FLAVOR COMPOSITION | April 2022 | September 2025 | Allow | 41 | 2 | 0 | No | No |
| 17716790 | AN EXTENDED RELEASE PHARMACEUTICAL COMPOSITION OF CLOZAPINE | April 2022 | December 2022 | Allow | 9 | 1 | 0 | Yes | No |
| 17763740 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF PANCREATITIS | March 2022 | May 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17702850 | Multifunctional Nanoparticles For Prevention And Treatment Of Atherosclerosis | March 2022 | January 2024 | Abandon | 22 | 2 | 0 | No | No |
| 17696984 | NEW DRY POWDER COMPOSITION FOR PERORAL ADMINISTRATION | March 2022 | July 2023 | Allow | 16 | 2 | 0 | No | No |
| 17695881 | Oxcarbazepine Extended Release Dosage Form | March 2022 | January 2024 | Allow | 22 | 4 | 0 | Yes | No |
| 17417645 | EXTERNAL PREPARATION | March 2022 | June 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17687160 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | March 2022 | March 2025 | Allow | 36 | 2 | 0 | No | No |
| 17683732 | OSMOTIC DOSAGE FORMS COMPRISING DEUTETRABENAZINE AND METHODS OF USE THEREOF | March 2022 | June 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17638368 | ANTI-PATHOGEN COMPOSITIONS | February 2022 | July 2024 | Allow | 28 | 1 | 0 | Yes | No |
| 17634791 | ORAL PHARMACEUTICAL COMPOSITION | February 2022 | September 2024 | Abandon | 31 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner TRAN, SUSAN T.
With a 51.9% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 27.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner TRAN, SUSAN T works in Art Unit 1615 and has examined 1,331 patent applications in our dataset. With an allowance rate of 61.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner TRAN, SUSAN T's allowance rate of 61.1% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by TRAN, SUSAN T receive 2.38 office actions before reaching final disposition. This places the examiner in the 68% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by TRAN, SUSAN T is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +35.2% benefit to allowance rate for applications examined by TRAN, SUSAN T. This interview benefit is in the 83% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 20.3% of applications are subsequently allowed. This success rate is in the 22% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 39.5% of cases where such amendments are filed. This entry rate is in the 60% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 83.4% of appeals filed. This is in the 77% percentile among all examiners. Of these withdrawals, 57.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 51.7% are granted (fully or in part). This grant rate is in the 51% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 16.2% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.0% of allowed cases (in the 61% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.